William Shomali
Overview
Explore the profile of William Shomali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zanotti R, Bonifacio M, Lucchini G, Sperr W, Scaffidi L, van Anrooij B, et al.
Leukemia
. 2021 Sep;
36(2):516-524.
PMID: 34545185
In the current classification of the World Health Organization (WHO), bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence...
12.
Shomali W, Gotlib J
Am J Hematol
. 2021 Sep;
97(1):129-148.
PMID: 34533850
Disease Overview: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary or clonal) disorders with potential for end-organ damage. Diagnosis: Hypereosinophilia (HE) has generally been...
13.
Shomali W, Damnernsawad A, Theparee T, Sampson D, Morrow Q, Yang F, et al.
Blood Adv
. 2021 Sep;
5(18):3581-3586.
PMID: 34496019
Hypereosinophilia (HE) has been defined as persistent eosinophilia >1.5 × 109/L; it is broadly divided into primary HE (clonal or neoplastic; HEN), secondary/reactive HE (HER), or HE of undetermined significance...
14.
Schwede M, Gotlib J, Shomali W
Clin Adv Hematol Oncol
. 2021 Jul;
19(7):450-459.
PMID: 34236344
Chronic neutrophilia is commonly seen with persistent infections, inflammatory disorders, smoking, solid tumors, and specific medications. However, after reactive causes have been excluded, a workup for primary (clonal) neutrophilic disorders,...
15.
Naumann N, Lubke J, Shomali W, Reiter L, Horny H, Jawhar M, et al.
Br J Haematol
. 2021 Jun;
194(2):344-354.
PMID: 34060083
We report on 45 patients with myeloid neoplasms and concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V (JAK2 /KIT ) mutations, which are individually...
16.
Shomali W, Gotlib J
Int J Mol Sci
. 2021 Apr;
22(6).
PMID: 33804174
Systemic mastocytosis (SM) is a rare clonal hematologic neoplasm, driven, in almost all cases, by the activating D816V mutation that leads to the growth and accumulation of neoplastic mast cells....
17.
Azizi A, Ediriwickrema A, Dutta R, Patel S, Shomali W, Medeiros B, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2700-2707.
PMID: 32543932
Treatment with hypomethylating agents (HMAs) azacitidine or decitabine is the current standard of care for high risk myelodysplastic syndromes (MDSs) but is associated with low rates of response. The limited...
18.
Shomali W, Brar R, Arekapudi S, Gotlib J
Hemoglobin
. 2019 Oct;
43(4-5):273-276.
PMID: 31657650
High oxygen affinity hemoglobins (Hbs), characterized by a decreased ability to release oxygen to the tissues and a left-shifted oxygen dissociation curve, are a rare cause of secondary erythrocytosis. Here,...
19.
Shomali W, Gotlib J
Am J Hematol
. 2019 Aug;
94(10):1149-1167.
PMID: 31423623
Disease Overview: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. Diagnosis: Hypereosinophilia has generally been defined as...
20.